Window of Opportunity Study Targeting the Inflammatory Milieu

Inclusion Criteria: * Age greater or equal to 18 and less than or equal to 50. * Histological or cytological confirmation of breast cancer; for patients with fine needle aspiration (FNA), a core biopsy must be intended * For patients diagnosed with needle core or excisional biopsy, formalin-fixed paraffin embedded tumor blocks or unstained slides must be available or patient must be willing to undergo repeat core biopsy for research purposes as part of study procedures (biopsy for fresh/ fresh frozen tissue is otherwise optional) * Any clinical stage allowed provided definitive local resection intended and neoadjuvant treatment not intended * Patient must be planned to proceed to definitive surgery for their breast cancer at least 1 week or more after diagnosis * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patient must have laboratory parameters as follows: * Liver function tests (Total bilirubin, aspartate aminotransferase, alanine aminotrasferase, alkaline phasphataseAST) =\< 2 x ULN * Platelet count greater than or equal to institutional lower limit of normal (LLN) * Patient cannot have greater than grade 1 anemia as determined by hematocrit (Hct) * Written informed consent obtained prior to any initiation of study procedures * Willingness to abstain from either fish oil or celebrex for study period if randomized to control arm * Women who are lactating at time of diagnosis are eligible provided they complete weaning prior to starting study drug …